Literature DB >> 24771458

The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.

Arnon Broides1, Nurit Hadad, Jacov Levy, Rachel Levy.   

Abstract

PURPOSE: The role of the Bruton tyrosine kinase (Btk) protein in neutrophil function has been evaluated using neutrophils from healthy volunteers after incubation with a Btk inhibitor, leflunomide metabolite analog (LFM-A13), suggesting an important role for Btk in neutrophil function. We sought to determine the role of Btk protein on neutrophil superoxide generation and chemotaxis stimulated by N-formyl-methionine-leucine-phenylalanine (fMLP).
METHODS: Chemotaxis was assayed on agarose gel and superoxide generation by cytochrome C reduction. The affects of LFM-A13 on chemotaxis and superoxide generation in unstimulated and fMLP stimulated neutrophils were studied in Btk deficient neutrophils from XLA patients compared with matched controls analyzed simultaneously.
RESULTS: Chemotaxis and stimulated superoxide production were similar in the normal and Btk deficient neutrophils and were similarly inhibited by LFM-A13. In one patient, LFMA13 had no effect on superoxide generation in Btk deficient neutrophils up to a concentration of 25 microM, while inhibited superoxide production by control neutrophils.
CONCLUSIONS: Our results suggest that Btk does not have a specific role in neutrophil fMLP-stimulated superoxide generation and chemotaxis since these activities were similarly inhibited by LFM-A13 in Btk deficient and normal neutrophils. The lack of superoxide generation following Btk inhibition by LFM-A13 in Btk deficient neutrophils from one patient may suggest some heterogeneity in the role of Btk in fMLP induced neutrophil superoxide generation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24771458     DOI: 10.1007/s10875-014-0046-z

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  26 in total

Review 1.  Genetic analysis of patients with defects in early B-cell development.

Authors:  Mary Ellen Conley; Arnon Broides; Vivian Hernandez-Trujillo; Vanessa Howard; Hirokazu Kanegane; Toshio Miyawaki; Sheila A Shurtleff
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

2.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

3.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

4.  Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia.

Authors:  Katja Fiedler; Anca Sindrilaru; Grzegorz Terszowski; Enikö Kokai; Thorsten B Feyerabend; Lars Bullinger; Hans-Reimer Rodewald; Cornelia Brunner
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

5.  Role of different protein tyrosine kinases in fMLP-induced neutrophil transmigration.

Authors:  Ke Zen; Yuan Liu
Journal:  Immunobiology       Date:  2007-09-10       Impact factor: 3.144

6.  Vitamin C for the treatment of recurrent furunculosis in patients with imparied neutrophil functions.

Authors:  R Levy; O Shriker; A Porath; K Riesenberg; F Schlaeffer
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

7.  Monocyte dysfunction in patients with Gaucher disease: evidence for interference of glucocerebroside with superoxide generation.

Authors:  Y Liel; A Rudich; O Nagauker-Shriker; T Yermiyahu; R Levy
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

8.  Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.

Authors:  Fatih M Uckun
Journal:  Cell Cycle       Date:  2007-09-26       Impact factor: 4.534

Review 9.  Bruton's tyrosine kinase as a new therapeutic target.

Authors:  Fatih M Uckun; Heather E Tibbles; Alexei O Vassilev
Journal:  Anticancer Agents Med Chem       Date:  2007-11       Impact factor: 2.505

10.  Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk.

Authors:  W Ellmeier; S Jung; M J Sunshine; F Hatam; Y Xu; D Baltimore; H Mano; D R Littman
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  6 in total

Review 1.  Covalent Inhibition in Drug Discovery.

Authors:  Avick Kumar Ghosh; Indranil Samanta; Anushree Mondal; Wenshe Ray Liu
Journal:  ChemMedChem       Date:  2019-03-26       Impact factor: 3.466

2.  Negative Regulation of Tec Kinase Alleviates LPS-Induced Acute Kidney Injury in Mice via theTLR4/NF-κB Signaling Pathway.

Authors:  Wei Zhang; Ping Zhou; Xiao Jiang; Zhe Fan; Xingxin Xu; Fei Wang
Journal:  Biomed Res Int       Date:  2020-06-19       Impact factor: 3.411

3.  Inhibitor of Tec kinase, LFM-A13, decreases pro-inflammatory mediators production in LPS-stimulated RAW264.7 macrophages via NF-κB pathway.

Authors:  Fei Wang; Wei Zhang; Chao Wang; Xu Fang; Hao Cheng; Sheng Liu; Xu-Lin Chen
Journal:  Oncotarget       Date:  2017-05-23

Review 4.  Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.

Authors:  Jingjing Wu; Mingzhi Zhang; Delong Liu
Journal:  Oncotarget       Date:  2017-01-24

Review 5.  Second-generation inhibitors of Bruton tyrosine kinase.

Authors:  Jingjing Wu; Christina Liu; Stella T Tsui; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-09-02       Impact factor: 17.388

6.  Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.

Authors:  Samantha A Chalmers; Jing Wen; Jessica Doerner; Ariel Stock; Carla M Cuda; Hadijat M Makinde; Harris Perlman; Todd Bosanac; Deborah Webb; Gerald Nabozny; Jay S Fine; Elliott Klein; Meera Ramanujam; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2018-01-25       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.